Literature DB >> 18301070

HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz.

Zulma G Vitezica1, Brigitte Milpied, Christine Lonjou, Nicolas Borot, Terence Niel Ledger, Anne Lefebvre, Alain Hovnanian.   

Abstract

HLA typing, demographic and immunological risk factors for nevirapine and efavirenz reactions were studied in a French cohort of HIV patients. Cases with isolated rash were significantly associated with HLA-DRB101 allele. No liver toxicity was observed and no association was detected with the percentage of CD4 T-cells. This study suggests that HLA-DRB101 allele plays an important role in susceptibility to cutaneous reactions associated with nevirapine and efavirenz in HIV patients.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18301070     DOI： 10.1097/QAD.0b013e3282f37812

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  40 in total

Review 1.  Pharmacogenetics as a tool to tailor antiretroviral therapy: A review.

Authors:  Antonio Aceti; Laura Gianserra; Lara Lambiase; Alfredo Pennica; Elisabetta Teti
Journal:  World J Virol       Date:  2015-08-12

2.  Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics.

Authors:  Victor Asensi; Julio Collazos; Eulalia Valle-Garay
Journal:  World J Virol       Date:  2015-08-12

Review 3.  Antimicrobial stewardship's new weapon? A review of antibiotic allergy and pathways to 'de-labeling'.

Authors:  Jason Trubiano; Elizabeth Phillips
Journal:  Curr Opin Infect Dis       Date:  2013-12       Impact factor: 4.915

4.  Persistent high nevirapine blood level with DRESS syndrome 12 days after interruption of antiretroviral therapy.

Authors:  Alice Breining; Amelie Guihot; Dominique Warot; Ana Canestri; Gilles Peytavin; Francois Bricaire; Eric Caumes
Journal:  BMJ Case Rep       Date:  2009-03-17

Review 5.  Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.

Authors:  Michael N Neely; Natella Y Rakhmanina
Journal:  Clin Pharmacokinet       Date:  2011-03       Impact factor: 6.447

Review 6.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

Review 7.  Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.

Authors:  Rebecca Pavlos; Simon Mallal; David Ostrov; Yuri Pompeu; Elizabeth Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Jan-Feb

Review 8.  New approaches for predicting T cell-mediated drug reactions: A role for inducible and potentially preventable autoimmunity.

Authors:  Aaron W Michels; David A Ostrov
Journal:  J Allergy Clin Immunol       Date:  2015-08       Impact factor: 10.793

9.  HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients.

Authors:  Sirirat Likanonsakul; Tippawan Rattanatham; Siriluk Feangvad; Sumonmal Uttayamakul; Wisit Prasithsirikul; Preecha Tunthanathip; Emi E Nakayama; Tatsuo Shioda
Journal:  AIDS Res Ther       Date:  2009-10-21       Impact factor: 2.250

10.  A model and risk score for predicting nevirapine-associated rash among HIV-infected patients: in settings of low CD4 cell counts and resource limitation.

Authors:  Sasisopin Kiertiburanakul; Somnuek Sungkanuparph; Kumthorn Malathum; Siriorn Watcharananan; Boonmee Sathapatayavongs; Angkana Charoenyingwattana; Surakameth Mahasirimongkol; Wasun Chantratita
Journal:  Open AIDS J       Date:  2009-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.